Azitra (AZTR) Convertible Debt (2022)

Azitra (AZTR) posted Convertible Debt of $6.6 million for Q4 2022.

Azitra (AZTR) Convertible Debt (2022) Analysis & Trends

Azitra's Convertible Debt history runs 1 years deep, the most recent figure standing at $6.6 million for Q4 2022.

  • Quarterly Convertible Debt changed N/A year-over-year to $6.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $6.6 million (changed N/A YoY) and the FY2022 annual result came in at $6.6 million, changed N/A from the prior year.
  • Convertible Debt was $6.6 million for Q4 2022 at Azitra.
  • Across five years, Convertible Debt topped out at $6.6 million in Q4 2022 and bottomed at $6.6 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Nanobiotix 1,769.80 Bn 1,769.74 Bn -
2 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
3 BeOne Medicines 473.64 Bn 468.85 Bn 1.35 Bn
4 Vertex Pharmaceuticals 123.74 Bn 116.49 Bn 2.59 Bn
5 Regeneron Pharmaceuticals 71.73 Bn 62.97 Bn 3.31 Bn
6 Belite Bio 62.10 Bn 62.10 Bn -
7 Argenx Se 54.68 Bn 49.49 Bn 1.41 Bn
8 Alnylam Pharmaceuticals 38.13 Bn 35.12 Bn 959.66 Mn
9 Revolution Medicines 36.21 Bn 36.21 Bn -
10 Azitra 2.03 Mn 2.03 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 6.60 Mn